What You Should Know:
– COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer.
– Since April 2021 when she was hired as the company’s chief strategy officer, Miruna has helped spearhead a series of research collaborations focused on investigating racial disparities in cancer care and the drug development process, including partnerships with the University of Chicago Medicine and MedStar Health.
Recent Accomplishments Since Joining COTA
Since Sasu joined the company, COTA has announced a series of research collaborations focused on investigating racial disparities in cancer care and the drug development process. In 2021, COTA entered into a new partnership with the University of Chicago Medicine. This work specifically aims to investigate racial disparities of care in multiple myeloma patients to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer. Last year, COTA also announced a partnership with MedStar Health focused on addressing the lack of diversity in clinical trials and unequal access to care.
“I came to COTA because of my belief that real-world data and analytics can fundamentally improve outcomes for cancer patients,” said Miruna Sasu, president and CEO at COTA, Inc. “My grandfather was diagnosed with lung cancer shortly after we moved to this country. We were lucky he was able to enroll in a clinical trial that saved his life. However, my experience is not the norm. As president and CEO of COTA, I am committed to making clinical trials and cancer care more accessible and affordable to all people regardless of income, race, ethnicity, gender, or geography.”
